Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

NCT02728102 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

203

Enrollment

NIH

Sponsor class

Conditions

Multiple Myeloma

Interventions

PROCEDURE: Tumor Cell Collection
PROCEDURE: Autologous Stem Cell Transplant
DRUG: Melphalan
PROCEDURE: Leukapheresis
BIOLOGICAL: Myeloma vaccine
DRUG: GM-CSF
DRUG: Lenalidomide

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborators

[object Object]
[object Object]
[object Object]